Pope Ian, Clark Lucy V, Clark Allan, Ward Emma, Belderson Pippa, Stirling Susan, Parrott Steve, Li Jinshuo, Coats Timothy, Bauld Linda, Holland Richard, Gentry Sarah, Agrawal Sanjay, Bloom Benjamin M, Boyle Adrian, Gray Alasdair, Geraint Morris M, Notley Caitlin
Norfolk and Norwich University Hospital, Norwich, UK.
Norwich Clinical Trials Unit, Norwich Medical School, University of East Anglia, Norwich, UK.
Health Technol Assess. 2025 Jul;29(35):1-36. doi: 10.3310/JHFR0841.
The emergency department represents a potentially valuable opportunity to support smoking cessation. Evidence is lacking around the use of e-cigarettes in opportunistic settings like the emergency department.
To undertake a randomised controlled trial in people who smoke attending United Kingdom emergency departments, testing a brief intervention which included provision of an e-cigarette versus signposting to smoking cessation services, assessing smoking abstinence.
A two-arm pragmatic, multicentre, parallel-group, individually randomised, controlled superiority trial with an internal pilot, economic evaluation and mixed-methods process evaluation.
Six emergency departments across England and Scotland.
Adults who smoked daily, who were attending the emergency department for medical treatment or accompanying someone attending for medical treatment, were invited to participate. People were excluded if they had an expired carbon monoxide of < 8 parts per million, required immediate medical treatment, were in police custody, had a known allergy to nicotine, were daily e-cigarette users, were considered not to have capacity to consent or had already taken part in the trial.
Brief stop smoking advice, e-cigarette starter kit and referral to stop smoking services.
The primary outcome was biochemically validated sustained abstinence at 6 months. Those lost to follow-up, or not providing biochemical verification, were considered not to be abstinent. Secondary outcomes were: self-reported 7-day smoking abstinence, number of quit attempts, number of cigarettes per day, nicotine dependence and incidence of self-reported dry cough or mouth or throat irritation.
At 6 months, of 972 participants randomised, biochemically verified smoking abstinence was 7.2% in the intervention group and 4.1% in the control group (percentage difference = 3.3%) (95% confidence interval 0.3 to 6.3; = 0.032) [relative risk 1.76 (95% confidence interval 1.03 to 3.01)]. Self-reported 7-day abstinence at 6 months was 23.3% in the intervention group and 12.9% in the control group (percentage difference = 10.6%) (95% confidence interval 5.86 to 15.41; < 0.001) [relative risk 1.80 (95% confidence interval 1.36 to 2.38)]. Daily e-cigarette use was 39.4% in the intervention group and 17.5% in the control group at 6 months. No serious adverse events related to taking part in the trial were reported. The economic evaluation found the intervention was likely to be cost-effective, judged by the National Institute for Health and Care Excellence threshold. The process evaluation found the intervention to be acceptable to both staff delivering it and participants receiving it. The brief nature of the intervention was highly adaptable to context, and interviews demonstrated how the intervention supported different pathways towards cessation.
The inability to blind participants or researchers, the relatively low level of biochemical verification due to the nature of the population recruited and the fact that those in the control group did not receive usual care.
An opportunistic smoking cessation intervention comprising brief advice, an e-cigarette starter kit and referral to stop smoking services is effective for sustained smoking abstinence with few reported adverse events.
Future work will include testing other behaviour change interventions in the emergency department and adapting the Cessation of Smoking Trial in the emergency department intervention for other settings.
This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR129438.
急诊科是支持戒烟的一个潜在宝贵契机。在急诊科等机会性场所使用电子烟的相关证据尚缺。
对前往英国急诊科就诊的吸烟者开展一项随机对照试验,测试一种简短干预措施,该措施包括提供电子烟与指引至戒烟服务机构,评估戒烟情况。
一项双臂实用性、多中心、平行组、个体随机对照优势试验,设有内部试点、经济评估和混合方法过程评估。
英格兰和苏格兰的6家急诊科。
邀请每日吸烟、因就医前往急诊科或陪同他人就医的成年人参与。若呼出一氧化碳含量低于百万分之8、需要立即接受治疗、被警方拘留、已知对尼古丁过敏、每日使用电子烟、被认为无同意能力或已参加过该试验,则被排除在外。
简短戒烟建议、电子烟入门套件及转介至戒烟服务机构。
主要结局为6个月时经生化验证的持续戒烟情况。失访者或未提供生化验证者被视为未戒烟。次要结局包括:自我报告的7天戒烟情况、戒烟尝试次数、每日吸烟量、尼古丁依赖程度以及自我报告的干咳或口腔或喉咙刺激的发生率。
在972名随机分组的参与者中,6个月时,干预组经生化验证的戒烟率为7.2%,对照组为4.1%(百分比差异=3.3%)(95%置信区间0.3至6.3;P=0.032)[相对风险1.76(95%置信区间1.03至3.01)]。干预组6个月时自我报告的7天戒烟率为23.3%,对照组为12.9%(百分比差异=10.6%)(95%置信区间5.86至15.41;P<0.001)[相对风险1.80(95%置信区间1.36至2.38)]。6个月时,干预组每日使用电子烟的比例为39.4%,对照组为17.5%。未报告与参与试验相关的严重不良事件。经济评估发现,根据英国国家卫生与临床优化研究所的阈值判断,该干预措施可能具有成本效益。过程评估发现,该干预措施对于实施干预的工作人员和接受干预的参与者而言都是可接受的。该干预措施的简短性质高度适用于不同情境,访谈表明该干预措施如何支持不同的戒烟途径。
无法使参与者或研究人员设盲,由于所招募人群的性质,生化验证水平相对较低,且对照组未接受常规护理。
一项包括简短建议、电子烟入门套件及转介至戒烟服务机构的机会性戒烟干预措施对于持续戒烟有效,且报告的不良事件较少。
未来工作将包括在急诊科测试其他行为改变干预措施,并将急诊科戒烟试验干预措施调整应用于其他场所。
本摘要展示了由英国国家卫生与保健研究所(NIHR)卫生技术评估项目资助的独立研究,资助编号为NIHR129438。